LONDON, August 9, 2018 /PRNewswire/ -- Improved drug formulation tech-nology and sophisticated injection deices are converging to create opportunities for sustained release dosing. The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues.
Download the full report: https://www.reportbuyer.com/product/5483290
Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve com-pliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects.
What You Will Learn
• What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
• What are the major factors driving sustained release injectable drug demand?
• What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact?
• How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry?
• What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products?
• In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2022? What is their expected growth rate?
• What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?
Download the full report: https://www.reportbuyer.com/product/5483290
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/sustained-release-injectables-to-2024-300694831.html
SOURCE ReportBuyer
